{"disease":{"id":"non-hodgkin-lymphoma-b-cell","name":"non hodgkin lymphoma b cell"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06573099","title":"A Real-World Study on Extranodal Lymphoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT00626496","title":"Family Study of Lymphoproliferative Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01787409","title":"Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02847130","title":"Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03375619","title":"Long-term Follow-up Study of Patients Receiving CAR-T Cells","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT05421663","title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":439,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02631044","title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":false},{"nct_id":"NCT03984448","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":363,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04594642","title":"A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05518383","title":"B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT05826535","title":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT06526793","title":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01865617","title":"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT07519772","title":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04970901","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"ADC Therapeutics S.A.","has_results":false},{"nct_id":"NCT01953692","title":"A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01307267","title":"A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01000753","title":"Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03997968","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Cyteir Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoNano Medicine, Inc.","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT02362035","title":"ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Acerta Pharma BV","has_results":true},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT01655225","title":"A Study of LY3023414 in Participants With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT03223610","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":155,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03246906","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT04870853","title":"Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03598608","title":"Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06424379","title":"BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":135,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04254107","title":"A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":133,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04002947","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06561425","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Galapagos NV","has_results":false},{"nct_id":"NCT03017820","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":127,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05442515","title":"CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05260203","title":"MargheRITA (Remote Intelligence for Therapeutic Adherence)","phase":"NA","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Advice Pharma Group srl","has_results":false},{"nct_id":"NCT05050461","title":"Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma","phase":"NA","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"Versailles Hospital","has_results":false},{"nct_id":"NCT06238648","title":"Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT06386315","title":"Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03744676","title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":true},{"nct_id":"NCT04186520","title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT04082936","title":"A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":97,"lead_sponsor_name":"IGM Biosciences, Inc.","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04035434","title":"A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":93,"lead_sponsor_name":"CRISPR Therapeutics AG","has_results":true},{"nct_id":"NCT05415098","title":"Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT02223052","title":"Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04849416","title":"A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Eli Lilly and Company","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}